Topic: Risk factors - Primary Care
Friday, 05 August 2016
PCCJ Editor-in-Chief Mike Kirby reviews a recent large observational study in the BMJ which concludes that women with atrial fibrillation are at a higher risk of cardiovascular disease and death than men.
Thursday, 06 April 2017
The incidence and prevalence of cardiovascular diseases increase in older adults and are a common cause of morbidity and mortality. This article by Dr David Milne examines whether we can reduce cardiovascular risk in the elderly, and if so, should we try to do so?
Tuesday, 03 October 2017
NHS England has announced that millions of people are to be offered checks for high blood pressure, high cholesterol and atrial fibrillation at GP surgeries and local pharmacies, as part of a drive to prevent heart disease and early deaths.
Category: Have You Heard
Thursday, 14 March 2019
There appears to be an association between migraine and cardiovascular disease and especially ischaemic stroke. How real is the absolute risk, what may be the cause, and what, if anything should we tell our patients?
Thursday, 16 June 2016
Morbidity and mortality for women with COPD is increasing. This systematic review uncovers how women seem to experience COPD differently to men, and helps health care professionals to provide an individualised approach to caring for these patients.
Wednesday, 07 June 2017
Over recent years there has been growing attention on cardiovascular disease prevention through improved detection and management of the high risk conditions such as atrial fibrillation, high blood pressure and high cholesterol in different parts of the country. Dr Matt Kearney, National Clinical Director for Cardiovascular Disease Prevention describes a number of encouraging national developments.
Category: Have You Heard
Monday, 17 July 2017
A new study has announced the new QRISK3 cardiovascular disease risk prediction algorithm. The calculator is used to work out the risk of developing a heart attack or stroke over the next 10 years. The risk calculator is designed for use in the UK.
Category: Evidence in Practice
Monday, 12 September 2016
Two injectable antibody-based therapies inhibiting the activity of PCSK9 - alirocumab and evolucumab - have recently been licensed. This paper reviews the current status of lipid management, the actions of PCSK9, and the clinical trial results achieved with PCSK9 inhibitors in early studies.
Tuesday, 02 October 2018
This article reviews the important and growing role of the NHS Health Check in tackling some of the challenges in prevention and treatment of CVD and other non-communicable diseases.